Dean EurichDean Eurich, BSP, PhD

Office: 2-040 Li Ka Shing Center for Health Research Innovation
Mail: University of Alberta, Edmonton, AB, T6G 2E6
Phone: 780-492-6333
Fax: 780-492-7455
Email: deurich@ualberta.ca

 

 

 

 

Current Position

 AHFMR Population Health Investigator & CIHR New Investigator

Associate Professor, School of Public Health

Research Area

Dr. Eurich's area of interest is in clinical epidemiology and natural history of disease and patterns of health service delivery. Within those core areas, he has also been involved in research aimed at the optimal use of evidence based treatments and practice/policy improvement.

Current Research Activities

Currently, Dr. Eurich's main focus is on pharmacoepidemiological studies evaluating the impact of drug therapies on morbidity and mortality in patients with type 2 diabetes. Currently he is evaluating the safety and effectiveness of Sitagliptin in relation to other oral antidiabetic agents in patients with type 2 diabetes, which was funded by the Canadian Diabetes Association. Dr. Eurich also has an interest in evaluating health services and drug therapies in patients with Comorbid diabetes and heart failure.

Given the nature of his research, most of Dr. Eurich's studies involve the use of advanced biostatistical techniques. This includes the use of time-dependent survival analysis, nested case control designs, propensity scores, and matching techniques. In addition, time-series analyses are also used to model the natural history of disease and patterns of health service delivery and utilization.

Dr. Eurich is a member of the Alliance for Canadian Health Outcomes Research in Diabetes (ACHORD) which is a multidisciplinary (i.e. medicine, epidemiology, pharmacy, economics and health policy) and multi-sectorial (i.e. government and academia) collaboration of researchers in diabetes research, in Canada and internationally that aims to establish evidence-based policy relevant research.

 

Biography

Dr. Eurich has a pharmacy degree from the University of Saskatchewan,  Following this, he completed a hospital residency with the Regina Health District, a Masters degree in Pharmacy in 2003, and a PhD through the Faculty of Medicine and Dentistry at the University of Alberta.  Throughout is training Dr. Eurich has continued to practice as a clinical hospital pharmacist is various capacities.

Dr. Eurich is a Population Health Investigator supported by the Alberta Heritage Foundation for Medical Research, a CIHR New Investigator, and an Associate Professor in the School of Public Health at the University of Alberta. He is also a Research Associate with the Alliance for Canadian Health Outcomes Research in Diabetes Group (ACHORD) and a member of the ADI.  His current focus is on Health Outcomes in patients with Diabetes and Cardiovascular Disease.

 

Other Activities and Affiliations

2012 - current Board Member, National Research Council, Canadian Diabetes Association

2012 – current Scientific Officer, Canadian Diabetes Association, Personal Awards & Grants Committee

2011- current Board Member, Canadian Association of Population Therapeutics (CAPT)

2007-current Research Coordinating Committee, Alberta Diabetes Institute. University of Alberta 

Unique Research Contributions

Dr. Eurich's research into the potential benefits and risks of metformin in patients with diabetes and heart failure has directly resulted in drug labeling changes for the prescribing of metformin in people with comorbid heart failure within Health Canada (2010) and within the Food and Drug Administration in the United States (2008). In addition, his research in this area has been directly incorporated into the Canadian Diabetes Association 2008 Clinical Practice guidelines.

 

Selected Publications

Eurich DT, Majumdar SR, Tsuyuki RT, Johnson JA. Reduced mortality associated with the use of angiotensin-converting enzyme inhibitors in patients with type 2 diabetes mellitus. Diabetes Care 2004:27;1330-1334. [Impact factor 7.9] PMID: 15161784

Eurich DT, Simpson SH, Majumdar SR, Johnson JA. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus. Pharmacotherapy 2005; 25:810-816. [Impact factor 2.0] PMID: 15927899

 Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.  Diabetes Care 2005;28:2345-2351. Lead Article and Featured for Commentary: Inzucchi, SE. Metformin and heart failure: innocent until proven guilty. Diabetes Care 2005;28:2585-2587.  Featured for Commentary: Is it safe to use metformin in CHF patients? NEJM Journal Watch 2005;25:175. [Impact factor 7.9] PMID: 16186261

Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335;497;doi:10.1136/bmj.39314.620174.80 Featured for Commentary BIOMED Central Faculty of 1000 Medicine: evaluations for Eurich et al http://www.f1000medicine.com/article/id/1090854/evaluation. Featured for Commentary, Snoek FJ. Self management of type 2 diabetes. BMJ 2007; doi:10.1136/bmj.39315.443160.BE. Featured for Commentary, Which Antidiabetic Drugs Are Safest for People with Diabetes and Heart Failure? NEJM Journal Watch 2007; 3-3 PMID: 17761999 Featured for Commentary, Evidence for major benefits and harms of antidiabetic agents for diabetes with heart failure is limited. ACP Journal Club. 2008 Jan-Feb;148:4 & Evid. Based Med. 2008;13;9. Included in the DARE (The Database of Abstracts of Reviews of Effects): http://www.crd.york.ac.uk/CRDWeb/ ShowRecord.asp?View=Full&ID=12007008299.  [Impact factor 9.7] PMID: 18556629

Eurich DT, Gamble JM, Simpson SH, Johnson JA. The Darkening Cloud of Diabetes: Do Trends in Cardiovascular Risk Management Provide a Silver Lining? Diabetes Care 2008:31:2136-2142. [Impact factor 7.9] PMID: 18840767

Eurich DT, Tsuyuki RT, Majumdar SR, McAlister FA, Lewanczuk R, Shibata MC, Johnson JA. Metformin Treatment in Diabetes and Heart Failure: When Academic Equipoise Meets Clinical Reality? Trials 2009;10:12-18 [Impact fFactor 1.4] PMID 19203392

Eurich DT, Gamble JM, Marrie TJ, Majumdar SR.  Dysglycaemia and 90 day and 1 year Risks of Death or Readmission in Patients Hospitalized for Community-Acquired Pneumonia. Diabetologia 2010; 53(3): 497-503.  doi: 10.1007/s00125-009-1598-y; [Impact factor 6.4] PMID: 19936702

MacDonald MR, Eurich DT, Majumdar SR, Lewsey JD, Bhagra S, Jhund PS, Petrie MC, McMurray JJV, Petrie JR, McAlister  FA.  Treatment of Type 2 Diabetes and Outcomes in Patients with Heart Failure: A Nested Case-Control Study from the United Kingdom General Practice Research Database.  Diabetes Care 2010; 33(6): 1213-1218. [Impact Factor 7.3] PMID:  20299488

Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Changes in labelling for metformin use in patients with type 2 diabetes and heart failure: Documented safety outweighs theoretical risks. Open Medicine 2011; 5(1): 33-34. [Impact Factor n/a] PMID:  22046218.

Eurich DT, McAlister FA. Chapter 6 - Diabetes and Cardiovascular Disease in Alberta – Diabetes and Heart Failure. In Alberta Diabetes Atlas 2011. Institute of Health Economics 2011:89-96.